REL and lymphoma: To identify up-regulated components potentially representative of bypass signalling pathways that compensate for loss of CHK1 in Eμ-Myc/cRel−/− lymphoma cells [20], we further interrogated our (phospho)proteomic datasets (Supplementary Data File S1), focusing on those proteins and phosphopeptides that were elevated in Eμ-Myc/cRel−/− relative to WT Eμ-Myc lymphomas.